Suchergebnisse - "Buckup, Mark"

PubPharm (20)

1

An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

enthalten in: Nature | 2024

von LaMarche, N. | Hegde, S. | Park, M. | +35

2

Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

enthalten in: Nature medicine | 2023

von Magen, A. | Hamon, P. | Fiaschi, N. | +50

3

Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae

enthalten in: Nature medicine | 2023

von Thompson, R. | Simons, N. | Wilkins, L. | +135

4

The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals

enthalten in: Clinical proteomics | 2022

von Butler-Laporte, G. | Gonzalez-Kozlova, E. | Su, C. | +162

ErratumIn: Clin Proteomics. 2022 Nov 15;19(1):40. - PMID 36376796

5

A shift in lung macrophage composition is associated with COVID-19 severity and recovery

enthalten in: Science translational medicine | 2022

von Chen, S. | Park, M. | Del Valle, D. | +34

UpdateOf: bioRxiv. 2022 Jan 12;:. - PMID 35043110

6

Utilising low-cost, easy-to-use microscopy techniques for early peritonitis infection screening in peritoneal dialysis patients

enthalten in: Scientific reports | 2022

von Buckup, M. | Kaneda, J. | Birk, A. | +6

7

Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade

enthalten in: bioRxiv.org | 2022

von Magen, A. | Hamon, P. | Fiaschi, N. | +45

8

Spatial CRISPR genomics identifies regulators of the tumor microenvironment

enthalten in: Cell | 2022

von Dhainaut, M. | Rose, S. | Akturk, G. | +18

CommentIn: Nat Methods. 2022 May;19(5):517. - PMID 35545708

9

The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response

enthalten in: Nature cancer | 2022

von Cohen, M. | Giladi, A. | Barboy, O. | +16

CommentIn: Nat Cancer. 2022 Mar;3(3):265-267. - PMID 35352059

10

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma : a single-arm, open-label, phase 2 trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Marron, T. | Fiel, M. | Hamon, P. | +50

CommentIn: Lancet Gastroenterol Hepatol. 2022 Mar;7(3):198-199. - PMID 35065056